Optimal treatment for driver gene-negative non-small cell lung cancer (NSCLC) with brain metastases (BM) remains unclear, particularly regarding immune checkpoint inhibitor (ICI)-based combinations and local BM therapy.
Predictive biomarkers for intracranial efficacy are also undefined.
